Kraj: Izrael
Język: angielski
Źródło: Ministry of Health
ENTECAVIR AS MONOHYDRATE
TEVA ISRAEL LTD
J05AF10
FILM COATED TABLETS
ENTECAVIR AS MONOHYDRATE 0.5 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
ENTECAVIR
Entecavir teva is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: - Compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (ALT) levels. - Decompensated liver disease.
2020-10-31
• كيلع فيك يلديصلا لأسا .ةمامقلا ةيواح يف وأ يحصلا فرصلا هايم يف ةيودلأا ءاقلإ عنم ُ ي .ةئيبلا ةيامح يف ريبادتلا هذه دعاست .ةلمعتسملا ريغ ةيودلأا نم صلختلا 6 . ة ّ يفاضإ تامولعم :ىلع ا ً ضيأ ءاودلا يوتحي ،لا ّ عفلا ب ّ كرملا ىلإ ةفاضإ :غلم 0.5 عڨيت ريڨاكيتنإ Mannitol, Cellulose, microcrystalline )Avicel PH 101(, Maize Starch-Rx 1500 Pregelatinized, Crospovidone Type A, Magnesium Stearate, Poly (vinyl alcohol) partially hydrolysed (E1203), Titanium Dioxide (E171), Macrogol (polyethylene glycol) MW3350, Talc (E553b). :غلم 1 عڨيت ريڨاكيتنإ Mannitol, Cellulose, microcrystalline (Avicel PH 101), Maize Starch-Rx 1500 Pregelatinized, Crospovidone Type A, Magnesium Stearate, Poly (vinyl alcohol) partially hydrolyzed (E1203), Titanium Dioxide (E171), Macrogol (polyethylene glycol) MW3350, Talc (E553b), Iron oxide red (E172). :ةوبعلا يوحت اذامو ءاودلا ودبي فيك :غلم 0.5 عڨيت ريڨاكيتنإ يفو "05" هيلع شوقنم دحاو بناج يف ، )Off-white) يميرك ىتح ضيبأ هنول ريدتسم صرق . E" شقنلا هيلع رخلآا بناجلا :غلم 1 عڨيت ريڨاكيتنإ "1" هيلع شوقنم دحاو بناج يف ،رطشلل قيمع طخ عم ،يدرو ىتح حتاف يدرو هنول ريدتسم صرق ."E/E" شقنلا هيلع رخلآا بناجلا يفو .ةبوطرلل صامو ايلطم اصرق 30 ىلع ةنينقلا يوتحت .ايلطم اصرق 30 وأ 10 ،7 ىلع )رتسيلب( ةحيوللا يوتحت .تا ّ وبعلا ماجحأو عاونأ لك ق ّ وس ُ ت لا دق :هناونعو ليجستلا بحاصو ج ِ تن ُ ملا مسا ،.ض.م ةيودلأا ةعانصل عڨيت اڨكت-حتيپ ،3190 .ب .ص .ةحصلا ةرازو تاميلعت قفو 2021 طابش يف ةرشنلا ريرحت مت :ةح Przeczytaj cały dokument
Entecavir Teva 0.5mg and 1mg Tablets-LC-SPC 02/2021-notification ENTECAVIR TEVA 0.5 MG AND 1 MG PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Entecavir Teva 0.5 mg film-coated tablets Entecavir Teva 1 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Entecavir-Teva 0.5 mg: Each film coated tablet contains 0.5 mg entecavir (as monohydrate) Entecavir-Teva 1 mg: Each film coated tablet contains 1 mg entecavir (as monohydrate) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Entecavir- Teva 0.5 mg film-coated tablets: White to off-white, round-shaped tablet with “05” debossed on one side of the tablet and “E” on the other side. Entecavir - Teva 1 mg film-coated tablets: Light pink to pink, round-shaped tablet with deep score line, debossed with "1" on one side of the tablet and with “E/E” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Entecavir Teva is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: • compensated liver disease, evidence of active viral replication, and persistently elevated serum alanine aminotransferase (ALT) levels. • decompensated liver disease. _Paediatric population _ Entecavir Teva is not indicated for children and adolescents under 18 years old. For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be initiated by a physician experienced in the management of chronic hepatitis B infection. Posology _ _ _Compensated liver disease_ _Nucleoside naive patients:_ the recommended dose in adults is 0.5 mg once daily, with or without food. _ _ _Lamivudine-refractory patients_ (i.e. with evidence of viraemia while on lamivudine or the presence of lamivudine resistance [LV Przeczytaj cały dokument